文献速递中毒与环境急症儿科与产科急症消化、代谢与肾脏急症

阿片使用障碍药物使用时长与产后过量及死亡风险

Duration of Medication Use for Opioid Use Disorder and Risk of Postpartum Overdose and Death.
PubMed 文献 · JAMA Netw Open · 2026-10-01
一句话结论孕期及产后早期MOUD累积暴露天数越长,产后1年内过量或死亡风险越低(132天vs 1天aHR 0.52)。

该回顾性队列研究基于田纳西州Medicaid数据,纳入2007–2020年分娩、暴露窗(产前90天至产后41天)内至少1天配发MOUD(丁丙诺啡和/或纳曲酮)的9360例妊娠(7776人,年龄15–44岁)。主要终点为产后42–365天全因死亡或过量(阿片或非阿片)。产后1年死亡或过量风险1.58%(148例),中位事件时间186.5天;暴露窗内MOUD中位时长88天。MOUD时长越长风险越低,132天vs 1天aHR 0.52(95%CI 0.31–0.88)。

要点

  • 产后1年死亡或过量风险为1.58%(148/9360),中位事件时间186.5天,提示产后42天后仍需持续关注。
  • 暴露窗(产前90天至产后41天)内MOUD中位时长仅88天,不足132天暴露窗,提示治疗连续性有提升空间。
  • MOUD累积天数越长,产后42–365天死亡或过量风险越低,132天vs 1天aHR 0.52(95%CI 0.31–0.88)。
  • 暴露药物为丁丙诺啡和/或纳曲酮,重叠配药按日历日去重,每日只计一次。
  • 结论支持孕期及产后早期持续MOUD治疗,而非产后早期停药。

适用人群与场景

  • 田纳西州Medicaid(TennCare)参保者,2007–2020年分娩,年龄15–44岁,分娩孕周≥20周,暴露窗(产前90天至产后41天)内至少1天配发MOUD,且暴露期持续参保。
  • 场景为产后门诊/急诊/住院出院后随访期(产后42–365天),非院前或抢救室急性期。

诊断标准与关键阈值

  • 暴露定义:产前90天至产后41天(共132天暴露窗)内配发MOUD(丁丙诺啡和/或纳曲酮)的唯一、不重叠总天数,重叠配药去重后每个日历日只计一次。
  • 主要终点:产后42–365天首次全因死亡或过量(阿片或非阿片),来自住院、门诊和急诊索赔数据。

处置流程与药物剂量

  • 原文未提及具体药物剂量、给药途径、频次或目标值;仅涉及丁丙诺啡和/或纳曲酮的配发天数。

红旗征与不能漏的情况

  • 产后42–365天全因死亡或过量(阿片或非阿片)为主要终点事件,中位发生时间186.5天,需在产后随访中持续识别。

研究设计与关键结果

  • 回顾性队列研究,田纳西州Medicaid数据链接生命记录和医院出院数据,9360例妊娠(7776人),中位年龄27岁(IQR 24–31)。
  • 产后1年死亡或过量风险1.58%(148例),中位事件时间186.5天(IQR 92.5–258.8)。
  • 暴露窗内MOUD中位时长88天(IQR 43–111),暴露窗总长132天。
  • 多变量Cox模型:MOUD时长越长,死亡或过量风险越低,132天vs 1天aHR 0.52(95%CI 0.31–0.88)。
  • 原文未提及关键次要终点和不良事件的具体结果。

证据类型、等级与局限

  • 证据类型:回顾性队列研究(单州Medicaid数据,非随机,存在适应证混杂可能)。
  • 局限:回顾性设计、单中心/单州数据、基于索赔的暴露与结局定义、无法排除未测量混杂。

对床旁实践的改变

  • 支持孕期及产后早期持续配发MOUD而非产后早期中断,以降低产后1年内过量或死亡风险。
  • 适用人群为暴露窗内已接受丁丙诺啡和/或纳曲酮的产后个体;不适用于未接受MOUD者或暴露窗外人群。
  • 常见陷阱:将观察性关联误读为因果;原文未提供具体剂量方案,不能据此制定给药剂量。

指南或共识出处

  • 原文未提及指南或共识名称;来源为JAMA Netw Open发表的原始研究。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Overdose is the leading cause of maternal mortality in the US, yet evidence on how medications for opioid use disorder (MOUD) affect postpartum overdose and mortality risk is limited. It is unclear whether cumulative MOUD exposure during this period reduces overdose or death beyond 90 days post partum.

OBJECTIVE: To examine whether longer duration of MOUD dispensed during pregnancy and early post partum is associated with reduced overdose or death through 365 days post partum.

DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective cohort study of individuals delivering between 2007 and 2020, assessed through 1 year post partum or until the first outcome, through 2021. The study used Tennessee Medicaid (TennCare) data linked to vital records (birth and death certificates) and Tennessee Hospital Discharge Data. Participants were individuals aged 15 to 44 years with at least 1 day of dispensed MOUD during the exposure window (90 days before to 41 days after delivery), a delivery at least 20 weeks' gestation, and continuous TennCare enrollment during the exposure period. Data were analyzed from July 2024 to July 2026.

EXPOSURE: Total unique, nonoverlapping days of dispensed MOUD (buprenorphine and/or naltrexone) from 90 days before delivery through 41 days after delivery, with overlapping fills deduplicated so each calendar day was counted only once.

MAIN OUTCOMES AND MEASURES: The primary outcome was the first occurrence of all-cause death or overdose (opioid or nonopioid) from inpatient, outpatient, and emergency department claims 42 to 365 days post partum. Multivariable Cox proportional hazards models were used to estimate the association between MOUD days' supply and risk of death or overdose, adjusting for maternal and clinical characteristics.

RESULTS: The cohort included 9360 pregnancies among 7776 individuals (median [IQR] age at delivery, 27 [24-31] years). The 1-year postpartum risk of death or overdose was 1.58% (148 individuals), with a median (IQR) time to event of 186.5 (92.5-258.8) days. The median (IQR) MOUD duration during the 132-day exposure period was 88 (43-111) days. Longer MOUD duration was associated with lower risk of death or overdose, with the lowest hazard at 132 days' supply (adjusted hazard ratio for 132 vs 1 day, 0.52; 95% CI, 0.31-0.88).

CONCLUSIONS AND RELEVANCE: Longer duration of MOUD receipt during pregnancy and early post partum was associated with lower risk of overdose or death in the first year post partum, underscoring the importance of supporting continuous MOUD treatment during this period.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Kim A, Wiese AD, Osmundson S, et al. Duration of Medication Use for Opioid Use Disorder and Risk of Postpartum Overdose and Death. JAMA Netw Open. 2026. PMID: 42826020. doi:10.1001/jamanetworkopen.2026.37214

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。